Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03141398 | Comparing CGM and OGTT in Relation to Iron Overload Detected by Pancreas T2* MRI in High-Risk Hematology Group(CGMs) | withdrawn | — | 0 | Hamad Medical CorporationINDUSTRY | 0 | Jul 26, 2017 | clinicaltrials |
| NCT02658396 | GO-203-2C + Bortezomib For Relapsed Or Refractory MM | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 5, 2017 | clinicaltrials |
| NCT01236586 | RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT02408042 | Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) | withdrawn | Phase 1 / Phase 2 | 0 | Western Regional Medical CenterOTHER | 1 | Jun 27, 2017 | clinicaltrials |
| NCT00637117 | Intratumoral Dendritic Cell Vaccination Combined With Local Radiotherapy in Patients With Recurrent Lymphoma. | withdrawn | Phase 1 / Phase 2 | 0 | Baylor Research InstituteOTHER | 0 | Jun 12, 2017 | clinicaltrials |
| NCT02194374 | Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL) | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jun 12, 2017 | clinicaltrials |
| NCT02647190 | Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older | withdrawn | Phase 1 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 2, 2017 | clinicaltrials |
| NCT02829840 | Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jun 2, 2017 | clinicaltrials |
| NCT02595242 | Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma | withdrawn | Phase 1 | 0 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | May 23, 2017 | clinicaltrials |
| NCT02623920 | Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma(S-BR) | withdrawn | Phase 2 | 0 | University of ArizonaOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT02766842 | Evaluation of a New EUS Guided Biopsy Needle (SharkCore) Comparing to Standard EUS Needle (ProCore) | withdrawn | Phase 2 | 0 | Johns Hopkins UniversityOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT01483274 | Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation(AML) | withdrawn | Phase 1 | 0 | University of LouisvilleOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT02564536 | Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | May 8, 2017 | clinicaltrials |
| NCT02791919 | Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | May 3, 2017 | clinicaltrials |
| NCT02371577 | Evaluation of the Immune Restoration Potential Of Lenalidomide(Revlimid) | withdrawn | Phase 2 | 0 | University of California, San DiegoOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT02802163 | Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat | withdrawn | Phase 1 / Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Apr 25, 2017 | clinicaltrials |
| NCT02961816 | Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 21, 2017 | clinicaltrials |
| NCT01605981 | Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.(MACS1881) | withdrawn | Phase 4 | 0 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 20, 2017 | clinicaltrials |
| NCT02520102 | Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia | withdrawn | Phase 2 | 0 | SanofiINDUSTRY | 0 | Apr 20, 2017 | clinicaltrials |
| NCT02973191 | A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia(ORBIT) | withdrawn | Phase 1 / Phase 2 | 0 | CelgeneINDUSTRY | 7 | Apr 10, 2017 | clinicaltrials |
| NCT02527174 | A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia(VIAC) | withdrawn | Phase 1 | 0 | University of AlbertaOTHER | 1 | Apr 5, 2017 | clinicaltrials |
| NCT02067637 | Delayed Effects of Treatment in Cancer Survivors (DETECS)(DETECS) | withdrawn | — | 0 | University of Colorado, DenverOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT02724904 | Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | Mar 22, 2017 | clinicaltrials |
| NCT01843179 | Sulindac for Patients With AML | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT02402725 | A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma(UltraDex) | withdrawn | Phase 2 | 0 | Boston Medical CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT02167360 | Study of Efficacy and Safety of CTL019 in Adult ALL Patients | withdrawn | Phase 2 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Feb 14, 2017 | clinicaltrials |
| NCT01650467 | Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms(abl LMC) | withdrawn | — | 0 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Feb 1, 2017 | clinicaltrials |
| NCT02343679 | Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies | withdrawn | Phase 2 | 0 | Anne Beaven, MDOTHER | 1 | Feb 1, 2017 | clinicaltrials |
| NCT02578121 | UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 1 | Jan 23, 2017 | clinicaltrials |
| NCT01410929 | Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma(MM) | withdrawn | Phase 4 | 0 | DFINE Inc.INDUSTRY | 0 | Jan 20, 2017 | clinicaltrials |
| NCT01176422 | Telomere and Telomerase | withdrawn | — | 0 | University of Kansas Medical CenterOTHER | 1 | Jan 10, 2017 | clinicaltrials |
| NCT02487316 | A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib | withdrawn | Phase 4 | 0 | Jun ZhuOTHER | 1 | Dec 30, 2016 | clinicaltrials |
| NCT01520805 | Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome | withdrawn | Phase 2 | 0 | Cornerstone PharmaceuticalsINDUSTRY | 1 | Dec 29, 2016 | clinicaltrials |
| NCT01812720 | Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant(CARAMEL 2) | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 1 | Dec 19, 2016 | clinicaltrials |
| NCT00513188 | Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma | withdrawn | N/A | 0 | University of MiamiOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT00881387 | Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment | withdrawn | Phase 2 | 0 | University of MiamiOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT02861040 | Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | withdrawn | Phase 1 | 0 | Northwestern UniversityOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT02420938 | Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 6, 2016 | clinicaltrials |
| NCT01841814 | Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy(LYMPHOS) | withdrawn | Phase 4 | 0 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Dec 5, 2016 | clinicaltrials |
| NCT00226993 | Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides. | withdrawn | Phase 1 / Phase 2 | 0 | Stanford UniversityOTHER | 0 | Dec 1, 2016 | clinicaltrials |
| NCT02757248 | Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL | withdrawn | Phase 1 | 0 | Anne Beaven, MDOTHER | 0 | Dec 1, 2016 | clinicaltrials |
| NCT02653989 | Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | withdrawn | Phase 2 | 0 | Medivation, Inc.INDUSTRY | 1 | Nov 25, 2016 | clinicaltrials |
| NCT01704742 | Prospective Study of Lymphoproliferative Diseases | withdrawn | — | 0 | West Virginia UniversityOTHER | 2 | Nov 8, 2016 | clinicaltrials |
| NCT02756663 | Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma(PANORAMA-5) | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Nov 8, 2016 | clinicaltrials |
| NCT01244009 | A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002) | withdrawn | Phase 2 | 0 | Tesaro, Inc.INDUSTRY | 0 | Nov 7, 2016 | clinicaltrials |
| NCT01423539 | A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE) | withdrawn | Phase 2 | 0 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02115126 | Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant | withdrawn | Phase 2 | 0 | David Rizzieri, MDOTHER | 1 | Nov 1, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Jul 26, 2017source: clinicaltrials